MT-act is a preclinical stage CNRS spin-off biotech that devised MT-discover®, a unique discovery platform that generates small molecules to safely restore microtubule cytoskeleton function in age-related diseases. We successfully employed MT-discover® in the space of cardiology and now expect it to fuel additional programs in the CNS. At MT-act, we ambition to bring innovative drug products to the clinic as treatment for several chronic diseases to improve patient’s life.